When can we expect #APOL1 channel inhibitors get @fda.gov approval? @asnkidney.bsky.social @vertexpharm.bsky.social #amkd @kidneyfund.bsky.social
Posts by Tejas Patel MD
Interesting physiology study
Efficacy of Tonlamarsen in Patients with Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial | JACC www.jacc.org/doi/10.1016/... #ACC #hypertension
@jaccjournals.bsky.social
Debate on a phenotype that is poorly measured and managed in clinical practice. 13 minutes to measure BP is not a practical recommendation. #hypertension
Blood-Pressure Targets in Hypertension Management | New England Journal of Medicine www.nejm.org/doi/full/10....
Every line is a punch line!
Number Needed to Treat | New England Journal of Medicine www.nejm.org/doi/full/10....
Learned more about Edelman formula in Channel your enthusiasm podcast! 👌
@askrenal.bsky.social
Is there evidence for using dual RAS blockers (ACEI + ARB) in post-partum AKI due to Thrombotic Microangiopathy #TMA #AKI #RASi
How do you assess for relapse in anti-gbm nephritis with no circulating antibody on presentation. Diagnosed by biopsy, urinary finding and worsening renal function.
@askrenal.bsky.social #askrenal
Illusion of a perfect office blood pressure reading #nephsky
www.wsj.com/health/welln...
Illusion of a perfect office blood pressure reading #nephsky
www.wsj.com/health/welln...
It’s a frustrating long winding unpredictable bumpy road with random road blocks and check points. Been waiting for long too. #nephsky @askrenal.bsky.social
On YouTube channel?
drinkhoist.com/pages/whats-...
Osmolality in play….good marketing. Gatorade has a competition. Military vs athlete. Pick your choice and pump up the solution. #nephsky
Would need a robust legal defense counsel if we were to advocate for metformin below eGFR 30.
youtu.be/cQX-QXxwGvA?...
No event is an event! Brilliant advertisement.
Can relate to this…challenge for clinicians to engage patients with chronic disease. #blusky @volvocars.bsky.social